GlassScriptPhysician profile
Himali Jayakody
NPI 1346479854
$16,204.22
in general payments reported to CMS, 2019-2025
45 companies · $2,838 in 2025
The $2,838 reported for 2025 was more than what 82% of Neurology With Special Qualifications In Child Neurology providers received nationally (typical 2025 total: $275).
See the full distribution for Neurology with Special Qualifications in Child Neurology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,062 · 2020: $1,239 · 2021: $2,140 · 2022: $2,252 · 2023: $2,372 · 2024: $2,301 · 2025: $2,838.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,511.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,510.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $3,039.43 | 2019-2025 | Fintepla, Briviact, Nayzilam |
| Jazz Pharmaceuticals INC. | $1,707.84 | 2019-2025 | |
| Ucb Gmbh | $1,120.39 | 2019 | |
| Sunovion Pharmaceuticals INC. | $907.33 | 2019-2022 | |
| Neurelis, INC. | $891.60 | 2020-2025 | Valtoco |
| Supernus Pharmaceuticals, INC. | $694.02 | 2019-2025 | Qelbree |
| Eisai INC. | $657.49 | 2019-2023 | |
| Corium, LLC | $650.31 | 2021-2025 | Azstarys |
| Tris Pharma INC | $577.09 | 2019-2025 | Onyda Xr, Dyanavel Xr |
| Catalyst Pharmaceuticals, INC. | $545.01 | 2023-2025 | Fycompa |
| Ironshore Pharmaceuticals INC. | $524.43 | 2019-2024 | Jornay Pm |
| Aquestive Therapeutics, INC. | $508.24 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $445.60 | 2019-2025 | Hyqvia |
| Livanova USA, INC. | $433.08 | 2019-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Greenwich Biosciences, INC. | $371.83 | 2019-2021 |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sk Life Science, INC. | $339.36 | 2020-2023 | Xcopri |
| Acadia Pharmaceuticals INC | $286.64 | 2023-2025 | Daybue |
| Sumitomo Pharma America, INC. | $258.16 | 2023-2024 | Aptiom |
| Immedica Pharma US, INC. | $236.71 | 2022-2024 | |
| Neos Therapeutics, LP | $235.79 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $195.79 | 2019-2021 | |
| Collegium Pharmaceutical, INC. | $183.61 | 2025 | Jornay Pm |
| Intrabio INC | $139.09 | 2025 | Aqneursa |
| Zogenix INC. | $98.97 | 2021 | |
| Otter Pharmaceuticals, LLC | $94.29 | 2025 | Sympazan |
| Shire North American Group INC | $93.75 | 2019 | |
| Travere Therapeutics, INC. | $91.34 | 2019-2021 | |
| Upsher-Smith Laboratories LLC | $89.50 | 2019-2025 | |
| Biogen, INC. | $74.34 | 2022-2024 | Skyclarys, Spinraza |
| Azurity Pharmaceuticals, INC. | $73.14 | 2024-2025 | Zonisade |
| Biomarin Pharmaceutical INC. | $66.94 | 2019-2025 | Brineura |
| Biocodex, INC. | $62.89 | 2023-2024 | Diacomit |
| Arbor Pharmaceuticals, INC. | $62.85 | 2022 | |
| Vertical Pharmaceuticals, LLC | $62.45 | 2019-2024 | Relexxii |
| Teva Pharmaceuticals USA, INC. | $58.96 | 2024 | Austedo Xr |
| Adlon Therapeutics L.P. | $56.78 | 2019-2021 | |
| Noven Therapeutics, LLC | $50.79 | 2024-2025 | Xelstrym |
| Ptc Therapeutics, INC. | $46.65 | 2021-2023 | |
| Amneal Pharmaceuticals LLC | $42.79 | 2023 | Lyvispah |
| Medtronic, INC. | $33.33 | 2023 | Intellis Adaptivestim |
| Abbvie INC. | $21.80 | 2025 | |
| Avion Pharmaceuticals | $21.20 | 2023 | Methylphenidate Hydrochloride |
| Ns Pharma, INC. | $20.08 | 2022 | |
| Rhodes Pharmaceuticals L.P. | $16.87 | 2019 | |
| Mallinckrodt Enterprises LLC | $15.67 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Himali Jayakody listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.